Tuberculosis vaccines

IDrugs

Volumn 3, Issue 4, 2000, Pages 408-415

  Srivastava, Ranjana ^a   Srivastava, Brahm S ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0142132032     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Bloom BR, Murray CJ: Tuberculosis: commentary on a reemergent killer. Science (1992) 257:1055-1064.
2. Raviglione MC, Snider Jr DE, Kochi A: Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. J Am Med Assoc (1995) 273:220-226.
3. Raviglione MC, Dye C, Schmidt S, Kochi A: Assessment of worldwide tuberculosis control. WHO global surveillance and monitotoring project. Lancet (1997) 350:624-629.
4. Rodriguez LC, Smith PG: Tuberculosis in the developing countries and methods for its control. Trans R Soc Trop Med Hyg (1990) 84:739-744
5. Kochi A, Vareldzis B, Stylbo K: Multidrug resistant tuberculosis and its control. Res Microbiol (1993) 144:104-110.
6. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Bordich E, Fineberg HV, Mosteller F: Efficacy of BCG vaccine in the prevention of tuberculosis: meta analysis of the published literature. J Am Med Assoc (1994) 271:698-702.
7. Orme I: Beyond BCG: the potential for a more effective TB vaccine. Mol Med Today (1999) 5:487-492.
8. Wiegeshaus E, Balasubramanian V, Smith DW: Immunity to tuberculosis from the perspective of pathogenesis. Infect Immun (1989) 57:3671-3676.
9. Schlesinger LS. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J Immunol (1993) 150:2920-2930.
10. Davatelis G, Tekamp-Olson P, Wolpe SD, Hermsen K, Luedke C, Coit D, Merrywealther J, Cerami A: Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP) a novel monokine with inflammatory and chemokine properties. J Exp Med (1998) 167:1939-1944.
11. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ: in response to MIP 1 (and MIP-1). Science (1993) 260:355-359.
12. Taub DD, Lloyd AR, Conlon K: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion Preferential migration of activated CD4+ and CD8+ T cells to endothelial cells. J Exp Med (1993) 177:1809-1814.
13. Murphy WJ, Tian Z-G, Asai O, Funakoshi S, Rotter P, Henry M, Strieter RM, Kunkel SL, Longo DL, Taub DD: Chemokines and T lymphocyte activation: II. Facilitation of human T cell traficking In severe combined immunodeficieny mice. J Immunol (1996) 156: 2104-2111.
14. Chan J, Kaufmann SHE: Immune mechanisms of protection. In: Tuberculosis: Pathogenesis, Protection and Control, Bloom BR (Eds), ASM Press, USA (1994) 389-415.
15. Lucas S, Nelson AM: Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In: Tuberculosis: Pathogenesis, Protection and Control, Bloom BR (Eds), ASM Press, USA (1994) 503-513.
16. Sturgil-Keszycki S, Schlesinger P, Chakraborty P, Haddix PL, Collins HL, Fok AK, Allen RD, Gluck SL, Heuser J, Russell DG: Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton ATPase. Science (1994) 263:678-681
17. Orme IM, Collins FM: Adoptive protection of the M. tuberculosis infected lung: dissociation between cells that passively transfer protective immunity and those that transfer delayed - type hypersensitivity to tuberculin. Cell Immun (1984) 84:113-120.
18. Muller I, Cobbold S, Waldmann H, Kaufmann SHE: Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 55:2037-2041.
19. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL: Mice deficient in CD4+ cells have only transiently diminished levels of IFN-gamma yet succumb to tuberculosis. J Immunol (1999) 162:5407-5416.
20. Flynn JL, Goldstein M, Triebold KJ, Koller B, Bloom BR: MHC class I restricted T cells are required for resistance to M. tuberculosis infection. Proc Natl Acad Sci USA (1992) 89:12013-12017.
21. Kaufmann SHE: Immunity to intracellular bacteria. Annu Rev Immunol (1993) 11:129-163.
22. Mosmann TR, Cherwinski HM, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone: Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 136:2348-2357.
23. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR: Two types of mouse helper T cell clone III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays and monooclonal antibodies. J Exp Med (1987) 166:1229-1244.
24. Kindler V, Sapp Lu S, Lu S, Ino AP, Grau GE, Piguet PF, Vassilli P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 56:731-740.
25. Barnes PF, Abrams JS, Lu S, Sieling PA, Rea TH, Modlin RL: Patterns of cytokine production by Mycobacterium reactive human T cell clones. Infect Immun (1993a) 61:197-203.
26. Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL: Cytokine production at the site of disease in human tuberculosis. Infect Immun (1993) 61:3482-3489.
27. Barnes PF, Modlin RL, Ellner JJ: T-cell responses and cytokines. In: Tuberculosis: Pathogenesis, Protection and Control, Bloom BR (Eds), ASM Press, USA (1994) 417-435.
28. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM: Disseminated tuberculosis in IFNγ gene disrupted mice. J Exp Med (1993) 178:2243-2247.
29. Flynn JL, Chan J, Bloom BR: An essential role for IFN-γ in resistance to M. tuberculosis. J Exp Med (1993) 178:2249-2254.
30. Roberts AD, Sonnenberg MG, Ordway DJ, Furney SK, Brennan PJ, Belisle JT, Orme IM: Characteristics of protective immunity engendered by vaccination with mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology (1995) 85:502-508.
31. Juoanguy E, Altare F, Lamhamedi S, Revy P, Newport M, Levin M, Blanche S, Seboun E, Fischer A, Casanova J-L: IFN-γ receptor deficiency in an infant with fatal BCG infection. New Engl J Med (1996) 335:1956-1961.
32. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, Levin M: A mutation in interferon-γ receptor gene and susceptibility to mycobacterial infection. New Engl J Med (1996) 335:1941-1949.
33. Gazzinelli RT, Oswald IP, James SL, Sher A: IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ activated macrophages. J Immunol (1996) 148:1792-1796.
34. Appleberg R, Orme IM, de Sousa MIP, Silva MT: In vitro effects of IL-4 on IFN-γ induced macrophage activation. Immunology (1992) 76:553-559.
35. Hirsch CS, Hussain R, Toossi Z, Ellner JJ: Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci USA (1996) 93:3193-3198.
36. Flynn JL, Goldstein MM, Triebold KJ, Wolf S, Bloom BR: Interleukin(IL)-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol (1995) 155:2515-2524.
37. Castro G, Silva RA, Appleberg R: Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infection in mice. J Immunol (1995) 155:2013-2019.
38. Ladel CH, Blum C, Freher A, Reifenberg K, Kaufmann SHE. Protective role of γ/δ T cells and α/β T cells in tuberculosis. Eur J Immunol (1995) 25:2877-2881.
39. Noble A, Macary PA, Kemeny DM: IFN-γ and IL-4 regulate the growth and differentiation of CD8+ T cells into subpopulations with distinct cytokine profile. J Immunol (1995) 155:2928-2937.
40. Andersen P: Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Scan J Immunol (1997) 45:115-131.
41. Halverson DC, Schwartz GN, Carter C, Gress RE, Fowler SH. In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype. Blood (1997) 90:2089-2096.
42. Kaufmann SHE, Schwartz RH, Pardoll DM: Activation of γδ T cells in the primary immune response to Mycobacterium tuberculosis. Science (1989) 244:713-716.
43. Turner J, Dockrell HM: Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T-cells in vitro. Immunology (1996) 87:339-342.
44. Mutis T, Cornelisse YE, Ottenhoff TH: Mycobacteria induced CD4+ T cells that are cytotoxic and displayed Th1 like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels. Eur J Immunol (1993) 23:2189-2195.
45. Bancroft GJ, Schreiber RD, Unanue ER: Natural immunity: a T-cell-independent pathway of the macrophage activation defined In the seid mouse. Immunol Rev (1991) 124:5-24.
46. Bloom BR, Fine PEM: The BCG experience: Implications for future vaccines against tuberculosis. In: Tuberculosis: Pathogenesis, Protection and Control, Bloom BR (Eds), ASM Press, USA (1994) 531-557.
47. Fine EM: The BCG story: Lessons from the past and implications for the future. Rev Infect Dis (1989) 11 (Suppl 2):S353-S359.
48. Smith DW, Harding GE: Are current strains of BCG protective in animals? TRi/SCG/79.6.1. World Health Organization, Geneva (1979).
49. Pithie AD, Rahelu M, Kumararatne DS, Drysdale P, Gaston JS, Iles PB, Innes JA, Ellis CJ: Generation of cytolytic T cells in individuals infected by Mycobacterium tuberculosis and vaccinated with BCG. Thorax (1992) 57:695-701.
50. Russel DG: Intracellular parasitism: the contrasting styles of Leishmania and Mycobacterium. In: Strategies for Intracellular Survival of Microbes, Russell DG (Eds) (1994) 227-243.
51. Fine EM: Variation in protection by BCG: Implications of and for heterologous immunity. Lancet (1995) 3346:1339.
52. Altare F, Jouanguy E, Lamhamedi S, Doffinger R, Fischer A, Casanova JL, Vesterhus P, Holland SM, Abrahamsen TG, Bjerknes R: Familial disseminated infection due to atypical mycobacteria with childhood onset. Clin Infect Dis (1998) 27:822-825.
53. Hotokezawa H, Kitamura A, Matsumato S, Hanazawa S, Amano S, Yamada T: Internalization of Mycobacterium bovis Bacillus Calmette-Guérin into osteoblast-like MC3T3-E1 cells and bone resorptive responses of the cells against the infection. Scan J Immunol (1998) 47:453-458.
54. Murray PJ, Aldovini A, Young RA: Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci USA (1996) 93:934-939.
55. Hess J, Kaufmann SHE: Live antigen carriers as tools for improved anti-tuberculous vaccines. FEMS Immunol Med Microbiol (1999) 23:165-173.
56. Balasubramanian V, Pavelka MS, Bardarov SS, Martin J, Weisbrod TR, McAdam RA, Bloom BR, Jacobs Jr WR: Allelic exchange in Mycobacterium tuberculosis with long linear recombination substrates. J Bacteriol (1996) 178:273-279.
57. Guleria I, Telbaum R, McAdam A, Kalpana G: Auxotrophic vaccines for tuberculosis. Nat Med (1996) 2:334-337.
58. Jackson M, Phalen SW, Lagranderie M, Ensergueix D, Chavarot P, Marchal G, McMurray DN, Gicquel B, Guilhot C: Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect Immun (1999) 67:2867-2873.
59. De Iisle GW, Wilson T, Collins DM, Buddle BM: Vaccination with guinea pigs with nutritionally impaired avirulent mutants of Mycobacterium bovis protects against tuberculosis. Infect Immun (1999) 67:2624-2626.
60. Hart PD, Sutherland I: BCG and vole bacillus vaccines in prevention of tuberculosis in adolescence and early adult life. Br Med J (1977) 22:293-295.
61. Gupta HP, Singh NB, Mathur IS, Gupta SK: Mycobacterium habana, a new immunogenic strain in experimental tuberculosis of mice. Indian J Exp Biol (1979) 17:1190-1193.
62. Singh IG, Mukherjee R, Talwar GP: Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium w. Vaccine (1991) 9:10-14.
63. von Reyn CF, Marsh BJ, Weddell R, Lein AD, Tvaroha S, Morin P, Modlin JF. Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus positive subjects in the United States after a five dose schedule of Mycobacterium vaccae vaccine. Clin Infect Dis (1998) 27:1517-20.
64. Chaturvedi V, Srivastava A, Gupta HP, Srivastava BS: Protective antigens of Mycobacterium habana are distributed between peripheral and integral components of plasma membrane: a study in experimental tuberculosis of mouse. Vaccine (1999) 17:2882-2887.
65. Young DB, Kaufmann SHE, Hermans PWM, Thole JER: Mycobacterial protein antigens: a compilation. Mol Microbiol (1992) 6:133-145.
66. Mehra V, Gong JH, Iyer D, Lin Y, Boylen CT, Bloom BR, Barnes PF: Immune response to recombinant mycobacterial proteins in patients with tuberculosis infection and disease. J Infect Dis (1996) 174:431-434.
67. Vordemeier HM: T-cell recognition of mycobacterial antigens. European Resp J Suppl (1995) 8:657s-667s.
68. Wallis R: New approaches to identification of antigens in Mycobacterium tuberculosis. Infect Agents Dis (1996) 5:119-125.
69. Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, Mustafa AS, Jensen AK, Holm A, Rosenkrands I, Oftung F, Olobo J, Von Reyn F, Andersen P: Human T cell responses to the ESAT-6 antigen from Mycobacterium. J Infect Dis (1999) 179:637-645.
70. Abou-Zeid C, Garbe T, Lathigra R, Wilker H, Harboe M, Rook GAW, Young DB: Genetic and immunological analysis of Mycobacterium tuberculosis fibronectin-binding proteins. Infect Immun (1991) 59:2712-2718.
71. Belisle JT, Sievert T, Takayama K, Besra G: Identification of a mycolyltransferase from Mycobacterium tuberculosis and the coincident definition of the physiological function of antigen 85B. In: Program of the 30th Joint Conference on Tuberculosis and Leprosy, US-Japan Cooperative Medical Science Program. Colorado, USA (1995) 212-216.
72. Harth G, Lee B-Y, Wang J, Clemens DL, Horwitz MA: Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis. Infect Immun (1996) 64:3038-3047.
73. Chan J, Fan X, Hunter SW, Brennan PJ, Bloom BR: Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun (1991) 59:1823-1831.
74. DeGroot AS, Meister GE et al: A novel algorithm for the efficient identification of T-cell epitopes: prediction and testing of candidate tuberculosis vaccine peptides in genetically diverse populations. Vaccines (Cold Spring Harbor); In: Molecular approaches to the control of infectious diseases, Brown F, Norrby E, Burton D, Mekalanos J (Eds), Cold Spring Harbor Laboratory Press, NY, USA, Vol 96 (1996), 127-134.
75. Agrewala JN, Wilkinson RJ: Differential regulation of Th1 and Th2 cells by p91-110 and p21-40 peptides of the 16 kD alpha-crystallin antigen of Mycobacterium tuberculosis. Clin Exp Immunol (1998) 114:392-397.
76. Donnelly JJ, Ulmer JB, Shiver JW, Liu, MA: DNA vaccines. Phamacol Ther (1997) 74:195-205.
77. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, Orme IM, Baldwin S, D'Souza C, Drowart A, Lozes E, Vandenbussche P, Van Vooren JP, Liu MA, Ulmer JB: Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med (1996) 2(8):893-898.
78. Klinman DM, Yi A-K Beaucage SL, Conover J, Kreig AM: CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFN-γ. Proc Natl Acad Sci USA (1996) 93:2879-2883.
79. Xiang Z, Ertl HC: Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity (1995) 2:129-135
80. Huygen K: DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis (1998) 2(12):971-978.
81. Tascon RE, Colston MJ, Ragno S, Stravropoulos E, Gregory D, Lowrie DB: Vaccination against tuberculosis by DNA injection. Nat Med (1996) 2:888-892.
82. Denis O, Tanghe A, Palfliet K, Jurion F, van den Berg TP, Vanonckelen A, Ooms J, Saman E, Ulmer JB, Content J, Huygen K: Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun (1998) 66(4):1527-1533.
83. Bonato VLD, Lima VMF, Tascon RE, Lowrie DB, Silva CL: Identification and characterization of protective T cells hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun (1998) 66:169-75.
84. Velaz-Faircloth M, Cobb AJ, Horstman AL, Henry SC, Frothingham R: Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein. Infect Immun (1999) 67:4243-4250.
85. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ: Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun (1999) 67:1702-1707.
86. Lowrie DB, Tascon RE, Bonato VLD, Lima VMF, Faccioli LH, Stavropoulos E, Colston MJ, Hewinson RG, Moelling K, Silva CL: Therapy of tuberculosis in mice by DNA vaccination. Nature (1999) 400:269-271.
87. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S: Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun (1999) 67:4780-4786.
88. Lowrie D, Tascon RE, Colston MJ, Silva CL: Towards a DNA vaccine against tuberculosis. Vaccine (1994) 12:1537-1540.
89. Baldwin SL, D'Souza C, Roberts AD, Kelly BP, Frank AA, Lui MA, Ulmer JB, Huygen K, McMurray DH, Orme IM: Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun (1998) 66:2951-2959.